SCHEMBL959797

SCHEMBL959797

CC(C)NC(=O)c1cccc(-c2cc(-c3ccc(Nc4ccncc4)cc3)on2)c1

nearest known ligand 0.58

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PRKD1 Q15139 8/20 0.58
ROCK2 O75116 5/20 0.53
CYP3A4 P08684 1/20 0.53
CYP3A5 P20815 1/20 0.53
NPC1 O15118 2/20 0.48
RAB9A P51151 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 1/20 0.48
HTT P42858 1/20 0.48
PRKD3 O94806 1/20 0.47
PRKD2 Q9BZL6 1/20 0.47
ROCK1 Q13464 1/20 0.47
MLLT1 Q03111 1/20 0.47
TP53 P04637 1/20 0.45
HPGD P15428 1/20 0.45
PPARG P37231 2/20 0.44
PPARA Q07869 2/20 0.44
ERN1 O75460 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6923851 0.85 PRKD1 (0.63) PRKD1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL937644 0.85 NPC1 (0.67) PRKD1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL966138 0.84 PRKD1 (0.62) PRKD1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6922488 0.84 PRKD1 (0.62) PRKD1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6923923 0.80 PRKD1 (0.82) PRKD1ROCK2NPC1RAB9ASMN1; SMN2
SCHEMBL6924745 0.78 PRKD1 (0.54) PRKD1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL6923596 0.78 PRKD1 (0.68) PRKD1NPC1RAB9ASMN1; SMN2ALDH1A1
SCHEMBL957994 0.77 PRKD1 (0.81) PRKD1ALDH1A1PRKD3PRKD2
SCHEMBL6924477 0.76 PRKD1 (0.56) PRKD1ROCK2PRKD3PRKD2ROCK1
SCHEMBL964036 0.76 PRKD1 (0.66) PRKD1NPC1RAB9ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011009484-A1 ARYLPYRAZOLES AND ARYLISOXAZOLES AND THEIR USE AS PKD MODULATORS NOVARTIS AG (CH) 2011-01-27 WO disclosed